Review Manager (RevMan) [Computer program]. Version 5. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration; 2015. Available from: http://tech​.cochrane.org/Revman.

WinBUGS [Computer programme] version 1.4. Cambridge: MRC Biostatistics Unit, University of Cambridge; 2015. Available from: http://www​.mrc-bsu.cam​.ac.uk/software/bugs​/the-bugs-project-winbugs/

Adams LA, George J, Bugianesi E, Rossi E, De Boer WB, van der Poorten D, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2011;26(10):1536–1543. [PubMed: 21950746]

Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. Journal of Hepatology. 2005;42:132–138. [PubMed: 15629518]

Aida Y, Abe H, Tomita Y, Nagano T, Seki N, Sugita T, et al. Serum cytokeratin 18 fragment level as a noninvasive biomarker for non-alcoholic fatty liver disease. International Journal of Clinical and Experimental Medicine. 2014;7(11):4191–4198. [PMC free article: PMC4276188] [PubMed: 25550930]

Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology. 2008;135(4):1176–1184. [PubMed: 18718471]

Akcam M, Boyaci A, Pirgon O, Kaya S, Uysal S, Dundar BN. Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver. International Journal for Vitamin and Nutrition Research. 2011;81(6):398–406. [PubMed: 22673924]

Al-Jiffri O, Al-Sharif FM, Abd El-Kader SM, Ashmawy EM. Weight reduction improves markers of hepatic function and insulin resistance in type-2 diabetic patients with non-alcoholic fatty liver. African Health Sciences. 2013;13(3):667–672. [PMC free article: PMC3824460] [PubMed: 24250305]

Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, et al. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics. 2014;39(11):1276–1285. [PMC free article: PMC4046270] [PubMed: 24738701]

Aller R, de Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: a double blind randomized clinical trial. European Review for Medical and Pharmacological Sciences. 2011;15(9):1090–1095. [PubMed: 22013734]

Angulo P, George J, Day CP, Vanni E, Russell L, De la Cruz AC, et al. Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology. 2014;12(7):1163. [PMC free article: PMC4057997] [PubMed: 24342745]

Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45(4):846–854. [PubMed: 17393509]

Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015;149(2):389–397. [PMC free article: PMC4516664] [PubMed: 25935633]

Argo CK, Patrie JT, Lackner C, Henry TD, De Lange EE, Weltman AL, et al. Effects of n-3 fish oil on metabolic and histological parameters in NASH: A double-blind, randomized, placebo-controlled trial. Journal of Hepatology. 2015;62(1):190–197. [PMC free article: PMC4272639] [PubMed: 25195547]

Bae JC, Rhee EJ, Lee WY, Park SE, Park CY, Oh KW, et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: A 4-year retrospective longitudinal study. Diabetes Care. 2011;34(3):727–729. [PMC free article: PMC3041216] [PubMed: 21278140]

Balmer ML, Siegrist K, Zimmermann A, Dufour JF. Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis. Liver International. 2009;29(8):1184–1188. [PubMed: 19422479]

Belfort R, Harrison SA, Brown K, Darland C, Finch J, Hardies J, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. New England Journal of Medicine. 2006;355(22):2297–2307. [PubMed: 17135584]

Bell LN, Wang J, Muralidharan S, Chalasani S, Fullenkamp AM, Wilson LA, et al. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study. Hepatology. 2012;56(4):1311–1318. [PMC free article: PMC3432683] [PubMed: 22532269]

Borman MA, Ladak F, Crotty P, Pollett A, Kirsch R, Pomier-Layrargues G, et al. The Fatty Liver Index has limited utility for the detection and quantification of hepatic steatosis in obese patients. Hepatology International. 2013;7(2):592–599. [PubMed: 26201792]

Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology (Baltimore, Md). 2004;40(6):1387–1395. [PubMed: 15565570]

Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N, et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. American Journal of Gastroenterology. 2005;100(5):1082–1090. [PubMed: 15842582]

Catalano D, Martines GF, Tonzuso A, Pirri C, Trovato FM, Trovato GM. Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). Digestive Diseases and Sciences. 2010;55(11):3200–3206. [PubMed: 20165979]

Chan WK, Ida NH, Cheah PL, Goh KL. Progression of liver disease in non-alcoholic fatty liver disease: a prospective clinicopathological follow-up study. Journal of Digestive Diseases. 2014;15:545–552. [PubMed: 25060399]

Chan W-K, Sthaneshwar P, Mustapha NRN, Mahadeva S. Limited utility of plasma M30 in discriminating non-alcoholic steatohepatitis from steatosis - A comparison with routine biochemical markers. PLoS One. 2014;9(9) [PMC free article: PMC4153577] [PubMed: 25184298]

Chang Y, Jung H-S, Yun KE, Cho J, Cho YK, Ryu S. Cohort study of non-alcoholic fatty liver disease, nafld fibrosis score, and the risk of incident diabetes in a korean population. American Journal of Gastroenterology. 2013;108(12):1861–1868. [PubMed: 24100261]

Chang Y, Ryu S, Sung E, Woo H-Y, Oh E, Cha K, et al. Nonalcoholic fatty liver disease predicts chronic kidney disease in nonhypertensive and nondiabetic Korean men. Metabolism: Clinical and Experimental. 2008;57(4):569–576. [PubMed: 18328362]

Chen SM, Liu CY, Li SR, Huang HT, Tsai CY, Jou HJ. Effects of therapeutic lifestyle program on ultrasound-diagnosed nonalcoholic fatty liver disease. Journal of the Chinese Medical Association. 2008;71(11):551–558. [PubMed: 19015052]

Chiang HJ, Lin LH, Li CW, Lin CC, Chiang HW, Huang TL, et al. Magnetic resonance fat quantification in living donor liver transplantation. Transplantation Proceedings. 2014;46(3):666–668. [PubMed: 24767318]

Chon YE, Jung KS, Kim SU, Park JY, Park YN, Kim DY, et al. Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver International. 2014;34(1):102–109. [PubMed: 24028214]

Cichoz-Lach H, Celinski K, Prozorow-Krol B, Swatek J, Slomka M, Lach T. The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease. Medical Science Monitor. 2012;18(12):CR735–CR740. [PMC free article: PMC3560810] [PubMed: 23197236]

Crossan C, Tsochatzis EA, Longworth L, Gurusamy K, Davidson B, Rodriguez-Peralvarez M, et al. Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation. Health Technology Assessment (Winchester, England). 2015;19(9):1–410. [PMC free article: PMC4781028] [PubMed: 25633908]

Cui J, Ang B, Haufe W, Hernandez C, Verna EC, Sirlin CB, et al. Comparative diagnostic accuracy of magnetic resonance elastography vs. eight clinical prediction rules for non-invasive diagnosis of advanced fibrosis in biopsy-proven non-alcoholic fatty liver disease: a prospective study. Alimentary Pharmacology and Therapeutics. 2015;41(12):1271–1280. [PMC free article: PMC4532628] [PubMed: 25873207]

Cusi K, Chang Z, Harrison S, Lomonaco R, Bril F, Orsak B, et al. Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. Journal of Hepatology. 2014;60(1):167–174. [PubMed: 23973932]

Dasarathy S, Dasarathy J, Khiyami A, Joseph R, Lopez R, McCullough AJ. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. Journal of Hepatology. 2009;51(6):1061–1067. [PMC free article: PMC6136148] [PubMed: 19846234]

de Ledinghen V, Vergniol J, Foucher J, Merrouche W, Le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver International. 2012;32(6):911–918. [PubMed: 22672642]

de Marco R, Locatelli F, Zoppini G, Verlato G, Bonora E, Muggeo M. Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care. 1999;22(5):756–761. [PubMed: 10332677]

de Moura Almeida A, Cotrim HP, Barbosa DBV, de Athayde LGM, Santos AS, Bitencourt AGV, et al. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. World Journal of Gastroenterology. 2008;14(9):1415–1418. [PMC free article: PMC2693692] [PubMed: 18322958]

Demir M, Lang S, Schlattjan M, Drebber U, Wedemeyer I, Nierhoff D, et al. NIKEI: A New Inexpensive and Non-Invasive Scoring System to Exclude Advanced Fibrosis in Patients with NAFLD. PLoS One. 2013;8(3) [PMC free article: PMC3608644] [PubMed: 23555578]

Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology. 2006;4(12):1537–1543. [PubMed: 17162245]

Dvorak K, Stritesky J, Petrtyl J, Vitek L, Sroubkova R, Lenicek M, et al. Use of non-invasive parameters of non-alcoholic steatohepatitis and liver fibrosis in daily practice - An exploratory case-control study. PLoS One. 2014;9(10) [PMC free article: PMC4211730] [PubMed: 25350286]

Eckard C, Cole R, Lockwood J, Torres DM, Williams CD, Shaw JC, et al. Prospective histopathologic evaluation of lifestyle modification in nonalcoholic fatty liver disease: a randomized trial. Therapeutic Advances in Gastroenterology. 2013;6(4):249–259. [PMC free article: PMC3667474] [PubMed: 23814606]

Ekstedt M, Franzen LE, Holmqvist M, Bendtsen P, Mathiesen UL, Bodemar G, et al. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology. 2009;44(3):366–374. [PubMed: 19016382]

Ekstedt M, Franzen LE, Mathiesen UL, Kechagias S. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression. Scandinavian Journal of Gastroenterology. 2012;47:108–115. [PubMed: 22126450]

Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology (Baltimore, Md). 2014 [PubMed: 25125077]

El Azeem HA, Khalek ESA, El-Akabawy H, Naeim H, Khalik HA, Alfifi AA. Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. Journal of the Saudi Heart Association. 2013;25(4):239–246. [PMC free article: PMC3818636] [PubMed: 24198448]

Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. American Journal of Clinical Nutrition. 2014;99(3):535–542. [PubMed: 24401715]

Evans CD, Oien KA, MacSween RN, Mills PR. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? Journal of Clinical Pathology. 2002;55:689–692. [PMC free article: PMC1769755] [PubMed: 12195000]

Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40(4):820–826. [PubMed: 15382171]

Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V, et al. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics. 2014;40(10):1209–1222. [PubMed: 25267215]

Feldstein AE, Alkhouri N, De VR, Alisi A, Lopez R, Nobili V. Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. American Journal of Gastroenterology. 2013;108(9):1526–1531. [PubMed: 23752877]

Feldstein AE, Papouchado BG, Angulo P, Sanderson S, Adams L, Gores GJ. Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology. 2005;3:384–389. [PubMed: 15822044]

Feldstein AE, Wieckowska A, Lopez AR, Liu Y-C, Zein NN, McCullough AJ. Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: A multicenter validation study. Hepatology. 2009;50(4):1072–1078. [PMC free article: PMC2757511] [PubMed: 19585618]

Ferraioli G, Tinelli C, Lissandrin R, Zicchetti M, Dal Bello B, Filice G, et al. Controlled attenuation parameter for evaluating liver steatosis in chronic viral hepatitis. World Journal of Gastroenterology. 2014;20(21):6626–6631. [PMC free article: PMC4047351] [PubMed: 24914387]

Funatsu K, Yamashita T, Nakamura H. Coffee consumption is associated with a lower incidence of fatty liver in middle-aged men. Journal of Health Science. 2011;57(5):406–413.

Goh GBB, Pagadala MR, Dasarathy J, Unalp-Arida A, Sargent R, Hawkins C, et al. Clinical spectrum of non-alcoholic fatty liver disease in diabetic and non-diabetic patients. BBA Clinical. 2015;3:141–145. [PMC free article: PMC4661498] [PubMed: 26675585]

GRADE Working Group. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group website. 2011. [1 October 2011]. Available from: http://www​.gradeworkinggroup.org/

Grigorescu M, Crisan D, Radu C, Grigorescu MD, Sparchez Z, Serban A. A novel pathophysiological-based panel of biomarkers for the diagnosis of nonalcoholic steatohepatitis. Journal of Physiology and Pharmacology. 2012;63(4):347–353. [PubMed: 23070083]

Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European liver fibrosis panel and exploring simple markers. Hepatology. 2008;47(2):455–460. [PubMed: 18038452]

Hallsworth K, Fattakhova G, Hollingsworth K, Thoma C, Moore S, Taylor R, et al. Resistance exercise improves liver lipid, fat oxidation and glucose control in adults with non-alcoholic fatty liver disease independent of weight loss. Journal of Hepatology. 2011;54:S337. [PMC free article: PMC3152868] [PubMed: 21708823]

Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Day CP, et al. Resistance exercise improves liver fat and glucose control in people with non-alcoholic fatty liver disease. Diabetologia. 2011;54:S246–S247. [PMC free article: PMC3152868] [PubMed: 21708823]

Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, et al. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011;60(9):1278–1283. [PMC free article: PMC3152868] [PubMed: 21708823]

Hamabe A, Uto H, Imamura Y, Kusano K, Mawatari S, Kumagai K, et al. Impact of cigarette smoking on onset of nonalcoholic fatty liver disease over a 10-year period. Journal of Gastroenterology. 2011;46(6):769–778. [PubMed: 21302121]

Hamaguchi E, Takamura T, Sakurai M, Mizukoshi E, Zen Y, Takeshita Y, et al. Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis. Diabetes Care. 2010;33:284–286. [PMC free article: PMC2809266] [PubMed: 19880582]

Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology. 2009;49(1):80–86. [PubMed: 19053049]

Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. American Journal of Gastroenterology. 2003;98:2042–2047. [PubMed: 14499785]

Hashimoto Y, Hamaguchi M, Kojima T, Ohshima Y, Ohbora A, Kato T, et al. The modest alcohol consumption reduces the incidence of fatty liver in men: A population-based large-scale cohort study. Journal of Gastroenterology and Hepatology. 2015;30(3):546–552. [PubMed: 25238605]

Haukeland JW, Konopski Z, Eggesbø HB, Volkmann HL, Raschpichler G, Bjøro K, et al. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial. Scandinavian Journal of Gastroenterology. 2009;44(7):853–860. [PubMed: 19811343]

Health and Safety Legislation. The Ionising Radiation (Medical Exposure) Regulations 2000. 2000. [19 November 2015]. (Statutory Instrument 2000 No. 1059) Available from: http://www​.legislation​.hmso.gov.uk/si/si2000/20001059.htm.

Hepburn MJ, Vos JA, Fillman EP, Lawitz EJ. The accuracy of the report of hepatic steatosis on ultrasonography in patients infected with hepatitis C in a clinical setting: a retrospective observational study. BMC Gastroenterology. 2005;5:14. [PMC free article: PMC1087838] [PubMed: 15829009]

HH AK, Henderson J, Vanhoesen K, Ghishan F, Bhattacharyya A. Nonalcoholic fatty liver disease in children: a single center experience. Clinical Gastroenterology and Hepatology. 2008;6:799–802. [PubMed: 18486560]

Huang K-W, Leu H-B, Wang Y-J, Luo J-C, Lin H-C, Lee F-Y, et al. Patients with nonalcoholic fatty liver disease have higher risk of colorectal adenoma after negative baseline colonoscopy. Colorectal Disease. 2013;15(7):830–835. [PubMed: 23398678]

Hui AY, Wong VW, Chan HL, Liew CT, Chan JL, Chan FK, et al. Histological progression of non-alcoholic fatty liver disease in Chinese patients. Alimentary Pharmacology and Therapeutics. 2005;21:407–413. [PubMed: 15709991]

Imamura Y, Uto H, Hiramine Y, Hosoyamada K, Ijuin S, Yoshifuku S, et al. Increasing prevalence of diabetes mellitus in association with fatty liver in a Japanese population. Journal of Gastroenterology. 2014;49(10):1406–1413. [PubMed: 24170184]

Janczyk W, Lebensztejn D, Wierzbicka-Rucinska A, Mazur A, Neuhoff-Murawska J, Matusik P, et al. Omega-3 Fatty acids therapy in children with nonalcoholic Fatty liver disease: a randomized controlled trial. Journal of Pediatrics. 2015;166(6):1358–1363. [PubMed: 25771388]

Jenks SJ, Conway BR, Hor TJ, Williamson RM, Mclachlan S, Robertson C, et al. Hepatic steatosis and non-alcoholic fatty liver disease are not associated with decline in renal function in people with Type 2 diabetes. Diabetic Medicine. 2014;31(9):1039–1046. [PubMed: 24684407]

Joka D, Wahl K, Moeller S, Schlue J, Vaske B, Bahr MJ, et al. Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology. 2012;55(2):455–464. [PubMed: 21993925]

Jun MJ, Shim JH, Kim SY, Seo N, Kim KM, Lim YS, et al. Clinical implications of preoperative and intraoperative liver biopsies for evaluating donor steatosis in living related liver transplantation. Liver Transplantation. 2014;20(4):437–445. [PubMed: 24478019]

Junior WS, Nonino-Borges CB. Clinical predictors of different grades of nonalcoholic fatty liver disease. Obesity Surgery. 2012;22(2):248–252. [PubMed: 21598007]

Kasturiratne A, Weerasinghe S, Dassanayake AS, Rajindrajith S, de Silva AP, Kato N, et al. Influence of non-alcoholic fatty liver disease on the development of diabetes mellitus. Journal of Gastroenterology and Hepatology. 2013;28(1):142–147. [PubMed: 22989165]

Kawamura Y, Saitoh S, Arase Y, Ikeda K, Fukushima T, Hara T, et al. Three-dimensional magnetic resonance imaging for stringent diagnosis of advanced fibrosis associated with nonalcoholic steatohepatitis. Hepatology International. 2013;7(3):850–858. [PubMed: 26201922]

Khosravi S, Alavian SM, Zare A, Fereshtehnejad S-M, Daryani NE, Keramati MR, et al. Non-alcoholic fatty liver disease and correlation of serum alanin aminotransferase level with histopathologic findings. Hepatitis Monthly. 2011;11(6):452–458. [PMC free article: PMC3212791] [PubMed: 22087177]

Kim CH, Park JY, Lee KU, Kim JH, Kim HK. Fatty liver is an independent risk factor for the development of Type 2 diabetes in Korean adults. Diabetic Medicine. 2008;25(4):476–481. [PubMed: 18346164]

Kim D, Kim WR, Talwalkar JA, Kim HJ, Ehman RL. Advanced fibrosis in nonalcoholic fatty liver disease : Noninvasive assessment with MR elastography. Radiology. 2013;268(2):411–419. [PMC free article: PMC3721049] [PubMed: 23564711]

Kim NH, Kim JH, Kim YJ, Yoo HJ, Kim HY, Seo JA, et al. Clinical and metabolic factors associated with development and regression of nonalcoholic fatty liver disease in nonobese subjects. Liver International. 2014;34(4):604–611. [PubMed: 24382309]

Kim YS, Jung ES, Hur W, Bae SH, Choi JY, Song MJ, et al. Noninvasive predictors of nonalcoholic steatohepatitis in Korean patients with histologically proven nonalcoholic fatty liver disease. Clinical and Molecular Hepatology. 2013;19(2):120–130. [PMC free article: PMC3701844] [PubMed: 23837136]

Kleiner DE, Brunt EM, Van NM, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321. [PubMed: 15915461]

Koelblinger C, Krssak M, Maresch J, Wrba F, Kaczirek K, Gruenberger T, et al. Hepatic steatosis assessment with 1H-spectroscopy and chemical shift imaging at 3.0 T before hepatic surgery: reliable enough for making clinical decisions? European Journal of Radiology. 2012;81(11):2990–2995. [PubMed: 22770582]

Kruger FC, Daniels CR, Kidd M, Swart G, Brundyn K, van RC, et al. APRI: A simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH. South African Medical Journal. 2011;101(7):477–480. [PubMed: 21920102]

Kumar R, Rastogi A, Sharma MK, Bhatia V, Tyagi P, Sharma P, et al. Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: Diagnostic performance and clinicopathological correlation. Digestive Diseases and Sciences. 2013;58(1):265–274. [PubMed: 22790906]

Lassailly G, Caiazzo R, Hollebecque A, Buob D, Leteurtre E, Arnalsteen L, et al. Validation of noninvasive biomarkers (FibroTest, SteatoTest, and NashTest) for prediction of liver injury in patients with morbid obesity. European Journal of Gastroenterology and Hepatology. 2011;23(6):499–506. [PubMed: 21499110]

Lau K, Lorbeer R, Haring R, Schmidt CO, Wallaschofski H, Nauck M, et al. The association between fatty liver disease and blood pressure in a population-based prospective longitudinal study. Journal of Hypertension. 2010;28(9):1829–1835. [PubMed: 20577126]

Lavine JE, Schwimmer JB, Molleston JP, Chalasani NP, Rosenthal P, Murray KF, et al. Vitamin E, metformin or placebo for treatment of nonalcoholic fatty liver disease in children. Hepatology. 2010;52(Suppl S1):374A.

Lavine JE, Schwimmer JB, Natta ML, Molleston JP, Murray KF, Rosenthal P, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011;305(16):1659–1668. [PMC free article: PMC3110082] [PubMed: 21521847]

Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, et al. Non-alcoholic fatty liver disease and mortality among US adults: Prospective cohort study. BMJ. 2011;343(7836):1245. [PMC free article: PMC3220620] [PubMed: 22102439]

Lee JY, Kim KM, Lee SG, Yu E, Lim YS, Lee HC, et al. Prevalence and risk factors of non-alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. Journal of Hepatology. 2007;47(2):239–244. [PubMed: 17400323]

Lee K. Metabolic syndrome predicts the incidence of hepatic steatosis in Koreans. Obesity Research and Clinical Practice. 2010;4(3):e217–e224. [PubMed: 24345665]

Lee SS, Park SH, Kim HJ, Kim SY, Kim MY, Kim DY, et al. Non-invasive assessment of hepatic steatosis: prospective comparison of the accuracy of imaging examinations. Journal of Hepatology. 2010;52(4):579–585. [PubMed: 20185194]

Lee TH, Han SH, Yang JD, Kim D, Ahmed M. Prediction of advanced fibrosis in nonalcoholic fatty liver disease: An enhanced model of BARD score. Gut and Liver. 2013;7(3):323–328. [PMC free article: PMC3661965] [PubMed: 23710314]

Lee YI, Lim Y-S, Park HS. Colorectal neoplasms in relation to non-alcoholic fatty liver disease in Korean women: A retrospective cohort study. Journal of Gastroenterology and Hepatology. 2012;27(1):91–95. [PubMed: 21679251]

Lee Y-M, Sutedja DS, Wai C-T, Dan Y-Y, Aung M-O, Zhou L, et al. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatology International. 2008;2(2):196–201. [PMC free article: PMC2716847] [PubMed: 19669304]

Leuschner UF, Lindenthal B, Herrmann G, Arnold JC, Rössle M, Cordes HJ, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52(2):472–479. [PubMed: 20683947]

Lindor KD, Kowdley KV, Heathcote EJ, Harrison ME, Jorgensen R, Angulo P, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39(3):770–778. [PubMed: 14999696]

Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: a prospective study. Hepatology. 2014;60(6):1920–1928. [PMC free article: PMC4245360] [PubMed: 25103310]

Lupsor M, Badea R, Stefanescu H, Grigorescu M, Serban A, Radu C, et al. Performance of unidimensional transient elastography in staging non-alcoholic steatohepatitis. Journal of Gastrointestinal and Liver Diseases. 2010;19(1):53–60. [PubMed: 20361076]

Lupsor-Platon M, Feier D, Stefanescu H, Tamas A, Botan E, Sparchez Z, et al. Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: a prospective study. Journal of Gastrointestinal and Liver Diseases. 2015;24(1):35–42. [PubMed: 25822432]

Mahadeva S, Mahfudz AS, Vijayanathan A, Goh K-L, Kulenthran A, Cheah P-L. Performance of transient elastography (TE) and factors associated with discordance in non-alcoholic fatty liver disease. Journal of Digestive Diseases. 2013;14(11):604–610. [PubMed: 23859493]

Mahady SE, Wong G, Craig JC, George J. Pioglitazone and vitamin E for nonalcoholic steatohepatitis: a cost utility analysis. Hepatology. 2012;56(6):2172–2179. [PubMed: 22707355]

Malik R, Chang M, Bhaskar K, Nasser I, Curry M, Schuppan D, et al. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2009;24(4):564–568. [PubMed: 19378390]

Manousou P, Kalambokis G, Grillo F, Watkins J, Xirouchakis E, Pleguezuelo M, et al. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients. Liver International : Official Journal of the International Association for the Study of the Liver. 2011;31(5):730–739. [PubMed: 21457446]

Marsman HA, van der Pool AE, Verheij J, Padmos J, Ten Kate FJW, Dwarkasing RS, et al. Hepatic steatosis assessment with CT or MRI in patients with colorectal liver metastases after neoadjuvant chemotherapy. Journal of Surgical Oncology. 2011;104(1):10–16. [PubMed: 21381036]

Masaki K, Takaki S, Hyogo H, Kobayashi T, Fukuhara T, Naeshiro N, et al. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatology Research. 2013;43(11):1182–1189. [PubMed: 23551911]

Mathiesen UL, Franzen LE, Aselius H, Resjo M, Jacobsson L, Foberg U, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Digestive and Liver Disease. 2002;34(7):516–522. [PubMed: 12236486]

McPherson S, Stewart SF, Henderson E, Burt AD, Day CP. Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease. Gut. 2010;59(9):1265–1269. [PubMed: 20801772]

McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. Journal of Hepatology. 2014. (0) [PubMed: 25477264]

Mennesson N, Dumortier J, Hervieu V, Milot L, Guillaud O, Scoazec JY, et al. Liver steatosis quantification using magnetic resonance imaging: a prospective comparative study with liver biopsy. Journal of Computer Assisted Tomography. 2009;33(5):672–677. [PubMed: 19820490]

Morling JR, Fallowfield JA, Williamson RM, Robertson CM, Glancy S, Guha IN, et al. gamma-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study. Diabetologia. 2015;58(7):1484–1493. [PMC free article: PMC4473275] [PubMed: 25820150]

Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver International. 2012;32(6):902–910. [PubMed: 22435761]

National Guideline Centre. Cirrhosis: assessment and management of cirrhosis. London: National Guideline Centre; 2016. (NICE clinical guideline). {In development, NG number unknown, due to publish June 2016} Available from: https://www​.nice.org​.uk/guidance/indevelopment​/gid-cgwave0683 {update webpage when published}

National Institute for Health and Care Excellence. Managing overweight and obesity among children and young people: lifesyle weight management services. London: National Institute for Health and Care Excellence; 2013. (NICE public health guidance 47). Available from: http://guidance​.nice.org.uk/PH47.

National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London: National Institute for Health and Care Excellence; 2014. Available from: http://www​.nice.org.uk​/article/PMG20/chapter​/1%20Introduction%20and%20overview. [PubMed: 26677490]

National Institute for Health and Care Excellence. Managing overweight and obesity in adults - lifestyle weight management services. London: National Institute for Health and Care Excellence; 2014. (NICE public health guidance 53). Available from: http://guidance​.nice.org.uk/PH53.

National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance. 2nd edition. London: National Institute for Health and Clinical Excellence; 2008. Available from: http://www​.nice.org.uk​/media/C18/30/SVJ2PUBLICATION2008.pdf. [PubMed: 27905706]

National Institute for Health and Clinical Excellence. The guidelines manual. London: National Institute for Health and Clinical Excellence; 2012. Available from: http://publications​.nice​.org.uk/the-guidelines-manual-pmg6/ [PubMed: 27905714]

National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal 2013. 2nd edition. London: National Institute for Health and Clinical Excellence; 2013. Available from: http://publications​.nice.org.uk/pmg9. [PubMed: 27905712]

Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: A randomized placebo-controlled trial. Journal of Clinical Gastroenterology. 2009;43(10):990–994. [PubMed: 19448566]

Neuschwander-Tetri BA, Loomba R, Sanyal AJ, Lavine JE, Van Natta ML, Abdelmalek MF, et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. The Lancet. 2015;385(9972):956–965. [PMC free article: PMC4447192] [PubMed: 25468160]

Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, Tonascia J, et al. Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. Hepatology. 2010;52(3):913–924. [PMC free article: PMC3070295] [PubMed: 20648476]

Nobili V, Alisi A, Della CC, Rise P, Galli C, Agostoni C, et al. Docosahexaenoic acid for the treatment of fatty liver: randomised controlled trial in children. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD. 2013;23(11):1066–1070. [PubMed: 23220074]

Nobili V, Parkes J, Bottazzo G, Marcellini M, Cross R, Newman D, et al. Performance of ELF Serum Markers in Predicting Fibrosis Stage in Pediatric Non-Alcoholic Fatty Liver Disease. Gastroenterology. 2009;136(1):160–167. [PubMed: 18992746]

Nobili V, Vizzutti F, Arena U, Abraldes JG, Marra F, Pietrobattista A, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology. 2008;48(2):442–448. [PubMed: 18563842]

Novielli N, Cooper NJ, Abrams KR, Sutton AJ. How is evidence on test performance synthesized for economic decision models of diagnostic tests? A systematic appraisal of Health Technology Assessments in the UK since 1997. Value in Health. 2010;13(8):952–957. [PubMed: 21029247]

Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2014. [15 January 2014]. Available from: http://www​.oecd.org/std/ppp.

Pacifico L, Bonci E, Di MM, Versacci P, Andreoli G, Silvestri LM, et al. A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD. 2015;25(8):734–741. [PubMed: 26026214]

Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. Journal of Hepatology. 2013;59:550–556. [PubMed: 23665288]

Palmentieri B, de Sio I, La Mura V, Masarone M, Vecchione R, Bruno S, et al. The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis. Digestive and Liver Disease. 2006;38(7):485–489. [PubMed: 16716779]

Palmeri ML, Wang MH, Rouze NC, Abdelmalek MF, Guy CD, Moser B, et al. Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. Journal of Hepatology. 2011;55(3):666–672. [PMC free article: PMC3092839] [PubMed: 21256907]

Paparo F, Cenderello G, Revelli M, Bacigalupo L, Rutigliani M, Zefiro D, et al. Diagnostic value of MRI proton density fat fraction for assessing liver steatosis in chronic viral C hepatitis. BioMed Research International. 2015;2015 758164. [PMC free article: PMC4383409] [PubMed: 25866807]

Papatheodoridis GV, Hadziyannis E, Tsochatzis E, Georgiou A, Kafiri G, Tiniakos DG, et al. Serum apoptotic caspase activity in chronic hepatitis C and nonalcoholic fatty liver disease. Journal of Clinical Gastroenterology. 2010;44(4):e87–e95. [PubMed: 19881359]

Park SK, Seo MH, Shin HC, Ryoo J-H. Clinical availability of non-alcoholic fatty liver disease as an early predictor of type 2 diabetes mellitus in Korean men: 5-year prospective cohort study. Hepatology. 2013;57(4):1378–1383. [PubMed: 23213066]

Pathik P, Ravindra S, Ajay C, Prasad B, Jatin P, Prabha S. Fibroscan versus simple noninvasive screening tools in predicting fibrosis in high-risk nonalcoholic fatty liver disease patients from western India. Annals of Gastroenterology. 2015;28(2):281–286. [PMC free article: PMC4367221] [PubMed: 25830783]

Perazzo H, Ngo Y, Lebray P, Seurat N, Rutka F, Couteau M, et al. Prognostic value of liver fibrosis and steatosis biomarkers in type-2 diabetes and dyslipidaemia. Alimentary Pharmacology and Therapeutics. 2014;40(9):1081–1093. [PubMed: 25186086]

Perez NE, Siddiqui FA, Mutchnick MG, Dhar R, Tobi M, Ullah N, et al. Ultrasound diagnosis of fatty liver in patients with chronic liver disease: a retrospective observational study. Journal of Clinical Gastroenterology. 2007;41(6):624–629. [PubMed: 17577120]

Perez-Gutierrez OZ, Hernandez-Rocha C, Candia-Balboa RA, Arrese MA, Benitez C, Brizuela-Alcantara DC, et al. Validation study of systems for noninvasive diagnosis of fibrosis in nonalcoholic fatty liver disease in Latin population. Annals of Hepatology. 2013;12(3):416–424. [PubMed: 23619258]

Petta S, Di M V, Camma C, Butera G, Cabibi D, Craxi A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: The effects of body mass index. Alimentary Pharmacology and Therapeutics. 2011;33(12):1350–1360. [PubMed: 21517924]

Pickhardt PJ, Hahn L, Munoz del Rio A, Park SH, Reeder SB, Said A. Natural history of hepatic steatosis: observed outcomes for subsequent liver and cardiovascular complications. AJR American Journal of Roentgenology. 2014;202(4):752–758. [PubMed: 24660702]

Pisto P, Santaniemi M, Bloigu R, Ukkola O, Kesaniemi YA. Fatty liver predicts the risk for cardiovascular events in middle-aged population: A population-based cohort study. BMJ Open. 2014;4(3) [PMC free article: PMC3963104] [PubMed: 24650811]

Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR, et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology. 2010;51(1):121–129. [PMC free article: PMC2799538] [PubMed: 19827166]

Pugh CJA, Cuthbertson DJ, Sprung VS, Kemp GJ, Richardson P, Umpleby AM, et al. Exercise training improves cutaneous microvascular function in nonalcoholic fatty liver disease. American Journal of Physiology Endocrinology and Metabolism. 2013;305(1):E50–E58. [PubMed: 23651847]

Qureshi K, Clements RH, Abrams GA. The utility of the “NAFLD fibrosis score” in morbidly obese subjects with NAFLD. Obesity Surgery. 2008;18(3):264–270. [PubMed: 18214632]

Raszeja-Wyszomirska J, Szymanik B, Lawniczak M, Kajor M, Chwist A, Milkiewicz P, et al. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD). BMC Gastroenterology. 2010;10:67. [PMC free article: PMC2905324] [PubMed: 20584330]

Ratziu V, Ledinghen V, Oberti F, Mathurin P, Wartelle-Bladou C, Renou C, et al. A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis. Journal of Hepatology. 2011;54(5):1011–1019. [PubMed: 21145828]

Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, et al. Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterology. 2006;6:6. [PMC free article: PMC1386692] [PubMed: 16503961]

Razavizade M, Jamali R, Arj A, Matini SM, Moraveji A, Taherkhani E. The effect of pioglitazone and metformin on liver function tests, insulin resistance, and liver fat content in nonalcoholic fatty liver disease: A randomized double blinded clinical trial. Hepatitis Monthly. 2013;13(5) [PMC free article: PMC3736624] [PubMed: 23930133]

Reinehr T, Schmidt C, Toschke AM, Andler W. Lifestyle intervention in obese children with non-alcoholic fatty liver disease: 2-year follow-up study. Archives of Disease in Childhood. 2009;94(6):437–442. [PubMed: 19224892]

Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol. 2005;58(10):982–990. [PubMed: 16168343]

Ruffillo G, Fassio E, Alvarez E, Landeira G, Longo C, Dominguez N, et al. Comparison of NAFLD fibrosis score and BARD score in predicting fibrosis in nonalcoholic fatty liver disease. Journal of Hepatology. 2011;54(1):160–163. [PubMed: 20934232]

Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. Journal of Gastroenterology and Hepatology. 2014;29(11):1926–1931. [PubMed: 24910023]

Santos VN, Lanzoni VP, Szejnfeld J, Shigueoka D, Parise ER. Revista Brasileira De Pesquisas Médicas e Biológicas / Sociedade Brasileira De Biofísica [Et Al ] Brazilian Journal of Medical and Biological Research. [A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid]. 2003;36(6):723–729. [PubMed: 12792701]

Sanyal AJ, Abdelmalek MF, Suzuki A, Cummings OW, Chojkier M. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial. Gastroenterology. 2014;147(2):377–384. [PubMed: 24818764]

Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. New England Journal of Medicine. 2010;362(18):1675–1685. [PMC free article: PMC2928471] [PubMed: 20427778]

Sanyal AJ, Mofrad PS, Contos MJ, Sargeant C, Luketic VA, Sterling RK, et al. A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clinical Gastroenterology and Hepatology. 2004;2(12):1107–1115. [PubMed: 15625656]

Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan(): validation in chronic hepatitis C. Journal of Viral Hepatitis. 2012;19(4):244–253. [PubMed: 22404722]

Sasso M, Beaugrand M, de Ledinghen V, Douvin C, Marcellin P, Poupon R, et al. Controlled attenuation parameter (CAP): a novel VCTE guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis: preliminary study and validation in a cohort of patients with chronic liver disease from various causes. Ultrasound in Medicine and Biology. 2010;36(11):1825–1835. [PubMed: 20870345]

Schwimmer JB, Middleton MS, Behling C, Newton KP, Awai HI, Paiz MN, et al. Magnetic resonance imaging and liver histology as biomarkers of hepatic steatosis in children with nonalcoholic fatty liver disease. Hepatology (Baltimore, Md ). 2015;61(6):1887–1895. [PMC free article: PMC4670559] [PubMed: 25529941]

Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Calder PC, et al. Design and rationale of the WELCOME trial: a randomised, placebo controlled study to test the efficacy of purified long chain omega-3 fatty treatment in non-alcoholic fatty liver disease. Contemporary Clinical Trials. 2014;37(2):301–311. [PubMed: 24556343]

Scorletti E, Bhatia L, McCormick KG, Clough GF, Nash K, Hodson L, et al. Effects of purified eicosapentaenoic and docosahexaenoic acids in non-alcoholic fatty liver disease: Results from the *WELCOME study. Hepatology. 2014 [PubMed: 25043514]

Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology. 2009;7(10):1104–1112. [PMC free article: PMC3079239] [PubMed: 19523535]

Shargorodsky M, Omelchenko E, Matas Z, Boaz M, Gavish D. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering? Cardiovascular Diabetology. 2012;11:61. [PMC free article: PMC3471007] [PubMed: 22676459]

Sharma BC, Kumar A, Garg V, Reddy RS, Sakhuja P, Sarin SK. A Randomized Controlled Trial Comparing Efficacy of Pentoxifylline and Pioglitazone on Metabolic Factors and Liver Histology in Patients with Non-alcoholic Steatohepatitis. Journal of Clinical and Experimental Hepatology. 2012;2(4):333–337. [PMC free article: PMC3940593] [PubMed: 25755455]

Shen F, Zheng RD, Mi YQ, Wang XY, Pan Q, Chen GY, et al. Controlled attenuation parameter for non-invasive assessment of hepatic steatosis in Chinese patients. World Journal of Gastroenterology. 2014;20(16):4702–4711. [PMC free article: PMC4000506] [PubMed: 24782622]

Shen J, Chan HL, Wong GL, Chan AW, Choi PC, Chan HY, et al. Assessment of non-alcoholic fatty liver disease using serum total cell death and apoptosis markers. Alimentary Pharmacology and Therapeutics. 2012;36(11-12):1057–1066. [PubMed: 23066946]

Shiasi Arani K, Taghavi Ardakani A, Moazami Goudarzi R, Talari HR, Hami K, Akbari H, et al. Effect of vitamin E and metformin on fatty liver disease in obese children- randomized clinical trial. Iranian Journal of Public Health. 2014;43(10):1417–1423. [PMC free article: PMC4441895] [PubMed: 26060704]

Shibata M, Kihara Y, Taguchi M, Tashiro M, Otsuki M. Nonalcoholic fatty liver disease is a risk factor for type 2 diabetes in middle-aged Japanese men. Diabetes Care. 2007;30(11):2940–2944. [PubMed: 17666460]

Shields WW, Thompson KE, Grice GA, Harrison SA, Coyle WJ. The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): A pilot trial. Therapeutic Advances in Gastroenterology. 2009;2(3):157–163. [PMC free article: PMC3002518] [PubMed: 21180541]

Singh DK, Sakhuja P, Malhotra V, Gondal R, Sarin SK. Independent predictors of steatohepatitis and fibrosis in Asian Indian patients with non-alcoholic steatohepatitis. Digestive Diseases and Sciences. 2008;53(7):1967–1976. [PubMed: 18030620]

Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies. Clinical Gastroenterology and Hepatology. 2014. epublication. [PMC free article: PMC4208976] [PubMed: 24768810]

Sookoian S, Castano G, Burgueno AL, Gianotti TF, Rosselli MS, Pirola CJ. A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem. Clinical Biochemistry. 2009;42(7-8):624–629. [PubMed: 19071103]

Sorrentino P, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Vecchione R. Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin, HOMA-IR, and hypertension. American Journal of Gastroenterology. 2010;105(2):336–344. [PubMed: 19861959]

Spadaro L, Magliocco O, Spampinato D, Piro S, Oliveri C, Alagona C, et al. Effects of n-3 polyunsaturated fatty acids in subjects with nonalcoholic fatty liver disease. Digestive and Liver Disease. 2008;40(3):194–199. [PubMed: 18054848]

Speliotes EK, Massaro JM, Hoffmann U, Vasan RS, Meigs JB, Sahani DV, et al. Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study. Hepatology. 2010;51(6):1979–1987. [PMC free article: PMC3023160] [PubMed: 20336705]

Steadman R, Myers RP, Leggett L, Lorenzetti D, Noseworthy T, Rose S, et al. A health technology assessment of transient elastography in adult liver disease. Canadian Journal of Gastroenterology. 2013;27(3):149–158. [PMC free article: PMC3732152] [PubMed: 23516679]

Sullivan S, Kirk EP, Patterson B, Klein S. Effect of endurance exercise on non-alcoholic fatty liver disease. Gastroenterology. 2011;140(5 SUPPL. 1):S700.

Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease. Hepatology. 2012;55(6):1738–1745. [PMC free article: PMC3337888] [PubMed: 22213436]

Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterology. 2012;12 [PMC free article: PMC3266187] [PubMed: 22221544]

Sung KC, Kim BS, Cho YK, Park DI, Woo S, Kim S, et al. Predicting incident fatty liver using simple cardio-metabolic risk factors at baseline. BMC Gastroenterology. 2012;12:84. [PMC free article: PMC3502272] [PubMed: 22770479]

Sung KC, Wild SH, Byrne CD. Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. Journal of Hepatology. 2014;60(5):1040–1045. [PubMed: 24445219]

Tang A, Desai A, Hamilton G, Wolfson T, Gamst A, Lam J, et al. Accuracy of MR imaging-estimated proton density fat fraction for classification of dichotomized histologic steatosis grades in nonalcoholic fatty liver disease. Radiology. 2015;274(2):416–425. [PMC free article: PMC4314291] [PubMed: 25247408]

Targher G, Bertolini LF, Rodella S FAU, Tessari R, Tessari RF, Zenari LF, Lippi GF, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Cardiovascular and Metabolic Risk. 2005. (1935-5548 (Electronic)) [PubMed: 17519430]

Targher G, Mantovani A, Pichiri I, Mingolla L, Cavalieri V, Mantovani W, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of chronic kidney disease in patients with type 1 diabetes. Diabetes Care. 2014;37(6):1729–1736. [PubMed: 24696459]

Targher G, Valbusa F, Bonapace S, Bertolini L, Zenari L, Rodella S, et al. Non-Alcoholic Fatty Liver Disease Is Associated with an Increased Incidence of Atrial Fibrillation in Patients with Type 2 Diabetes. PLoS One. 2013;8(2) [PMC free article: PMC3579814] [PubMed: 23451184]

Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G, et al. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. Journal of the American Society of Nephrology. 2008;19(8):1564–1570. [PMC free article: PMC2488256] [PubMed: 18385424]

Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology. 1995;22:1714–1719. [PubMed: 7489979]

Thoma C, Hallsworth K, Hollingsworth K, Anstee Q, Taylor R, Day C, et al. High-intensity intermittent exercise therapy reduces liver fat and improves body composition in adults with non-alcoholic fatty liver disease. Journal of Hepatology. 2013;58:S550–S551. [PubMed: 23178979]

Thoma C, Hallsworth K, Hollingsworth K, Taylor R, Day CP, Trenell M. Unsupervised high-intensity intermittent training reduces liver fat and improves body composition in adults with non-alcoholic fatty liver disease (NAFLD). Diabetic Medicine. 2013;30:60.

Tock L, Damaso AR, de Piano A, Carnier J, Sanches PL, Lederman HM, et al. Long-term effects of metformin and lifestyle modification on nonalcoholic Fatty liver disease obese adolescents. Journal of Obesity. 2010;2010 [PMC free article: PMC2925435] [PubMed: 20798858]

Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. Journal of Hepatology. 1997;27(1):103–107. [PubMed: 9252081]

Urdzik J, Bjerner T, Wanders A, Weis J, Duraj F, Haglund U, et al. The value of pre-operative magnetic resonance spectroscopy in the assessment of steatohepatitis in patients with colorectal liver metastasis. Journal of Hepatology. 2012;56(3):640–646. [PubMed: 22027576]

Vajro P, Mandato C, Licenziati MR, Franzese A, Vitale DF, Lenta S, et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. Journal of Pediatric Gastroenterology and Nutrition. 2011;52(6):740–743. [PubMed: 21505361]

Van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Statistics in Medicine. 2002;21(4):589–624. [PubMed: 11836738]

Van Houwelingen HC, Zwinderman KH, Stijnen T. A bivariate approach to meta-analysis. Statistics in Medicine. 1993;12(24):2273–2284. [PubMed: 7907813]

van Werven JR, Marsman HA, Nederveen AJ, Smits NJ, ten Kate FJ, van Gulik TM, et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology. 2010;256(1):159–168. [PubMed: 20574093]

van Werven JR, Schreuder TCMA, Aarts EO, Nederveen AJ, Meijer JWR, Berends FJ, et al. Hepatic steatosis in morbidly obese patients undergoing gastric bypass surgery: assessment with open-system 1H-MR spectroscopy. AJR American Journal of Roentgenology. 2011;196(6):W736–W742. [PubMed: 21606262]

Verma S, Jensen D, Hart J, Mohanty SR. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver International. 2013;33(9):1398–1405. [PubMed: 23763360]

Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Annals of Hepatology. 2011;10(3):277–286. [PubMed: 21677329]

Wang CC, Hsieh TC, Tseng TC, Wang PC, Hsu CS, Lin HH, et al. Factors affecting the diagnostic accuracy of ultrasonography in assessing the severity of hepatic steatosis. Journal of the Formosan Medical Association. 2014;113(4):249–254. [PubMed: 24685301]

Wang CY, Lu W, Hu DS, Wang GD, Cheng XJ. Diagnostic value of controlled attenuation parameter for liver steatosis in patients with chronic hepatitis B. World Journal of Gastroenterology. 2014;20(30):10585–10590. [PMC free article: PMC4130870] [PubMed: 25132779]

Wang JH, Hung CH, Kuo FY, Eng HL, Chen CH, Lee CM, et al. Ultrasonographic quantification of hepatic-renal echogenicity difference in hepatic steatosis diagnosis. Digestive Diseases and Sciences. 2013;58(10):2993–3000. [PubMed: 23828144]

Webb M, Yeshua H, Zelber-Sagi S, Santo E, Brazowski E, Halpern Z, et al. Diagnostic value of a computerized hepatorenal index for sonographic quantification of liver steatosis. AJR American Journal of Roentgenology. 2009;192(4):909–914. [PubMed: 19304694]

Williams R, Ashton K, Aspinall R, Bellis MA, Bosanquet J, Cramp ME, et al. Implementation of the Lancet Standing Commission on Liver Disease in the UK. Lancet (London, England). 2015;386(10008):2098–2111. [PubMed: 26700394]

Williams R, Aspinall R, Bellis M, Camps-Walsh G, Cramp M, Dhawan A, et al. Addressing liver disease in the UK: A blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis. The Lancet. 2014;384(9958):1953–1997. [PubMed: 25433429]

Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years. Gut. 2010;59:969–974. [PubMed: 20581244]

Wong VWS, Vergniol J, Wong GLH, Foucher J, Chan AWH, Chermak F, et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. American Journal of Gastroenterology. 2012;107(12):1862–1871. [PubMed: 23032979]

Wong VWS, Vergniol J, Wong GLH, Foucher J, Chan HLY, Le BB, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51(2):454–462. [PubMed: 20101745]

Wong VWS, Wong GLH, Chim AML, Tse AML, Tsang SWC, Hui AY, et al. Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis. American Journal of Gastroenterology. 2008;103(7):1682–1688. [PubMed: 18616651]

Wong VWS, Wong GLH, Yip GWK, Lo AOS, Limquiaco J, Chu WCW, et al. Coronary artery disease and cardiovascular outcomes in patients with non-alcoholic fatty liver disease. Gut. 2011;60(12):1721–1727. [PubMed: 21602530]

Wong VW-S, Chan RS-M, Wong GL-H, Cheung BH-K, Chu WC-W, Yeung DK-W, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. Journal of Hepatology. 2013;59(3):536–542. [PubMed: 23623998]

Wong VW-S, Won GL-H, Chim AM-L, Chu WC-W, Yeung DK-W, Li KC-T, et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Annals of Hepatology. 2013;12(2):256–262. [PubMed: 23396737]

Wu CH, Ho MC, Jeng YM, Hsu CY, Liang PC, Hu RH, et al. Quantification of hepatic steatosis: a comparison of the accuracy among multiple magnetic resonance techniques. Journal of Gastroenterology and Hepatology. 2014;29(4):807–813. [PubMed: 24224538]

Xu C, Yu C, Ma H, Xu L, Miao M, Li Y. Prevalence and risk factors for the development of nonalcoholic fatty liver disease in a nonobese Chinese population: the Zhejiang Zhenhai Study. American Journal of Gastroenterology. 2013;108(8):1299–1304. [PubMed: 23567356]

Xun YH, Fan JG, Zang GQ, Liu H, Jiang YM, Xiang J, et al. Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease. Journal of Digestive Diseases. 2012;13(11):588–595. [PubMed: 23107446]

Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M. Ultrasonographical diagnosis of fatty liver: significance of the liver-kidney contrast. Tohoku Journal of Experimental Medicine. 1983;139(1):43–50. [PubMed: 6220488]

Yamada T, Fukatsu M, Suzuki S, Wada T, Yoshida T, Joh T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. Journal of Gastroenterology and Hepatology. 2010;25(2):352–356. [PubMed: 19817963]

Yamazaki H, Tsuboya T, Tsuji K, Dohke M, Maguchi H. Independent association between improvement of nonalcoholic fatty liver disease and reduced incidence of type 2 diabetes. Diabetes Care. 2015;38(9):1673–1679. [PubMed: 26156527]

Yilmaz Y, Dolar E, Ulukaya E, Akgoz S, Keskin M, Kiyici M, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World Journal of Gastroenterology. 2007;13(6):837–844. [PMC free article: PMC4065917] [PubMed: 17352011]

Yoneda M, Imajo K, Eguchi Y, Fujii H, Sumida Y, Hyogo H, et al. Noninvasive scoring systems in patients with nonalcoholic fatty liver disease with normal alanine aminotransferase levels. Journal of Gastroenterology. 2013;48(9):1051–1060. [PubMed: 23184095]

Yoneda M, Mawatari H, Fujita K, Endo H, Iida H, Nozaki Y, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Digestive and Liver Disease. 2008;40(5):371–378. [PubMed: 18083083]

Yoneda M, Suzuki K, Kato S, Fujita K, Nozaki Y, Hosono K, et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology. 2010;256(2):640–647. [PubMed: 20529989]

Yoneda M, Thomas E, Sumida Y, Imajo K, Eguchi Y, Hyogo H, et al. Clinical usage of serum ferritin to assess liver fibrosis in patients with non-alcoholic fatty liver disease: Proceed with caution. Hepatology Research. 2015;44(14):E499–E502. [PubMed: 24628717]

Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global Epidemiology of Non-Alcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence and Outcomes. Hepatology. 2015. epublication. [PubMed: 26707365]

Younossi ZM, Otgonsuren M, Henry L, Venkatesan C, Mishra A, Erario M, et al. Association of Non-alcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States from 2004-2009. Hepatology (Baltimore, Md). 2015 [PubMed: 26274335]

Younossi ZM, Page S, Rafiq N, Birerdinc A, Stepanova M, Hossain N, et al. A biomarker panel for non-alcoholic steatohepatitis (NASH) and NASH-related fibrosis. Obesity Surgery. 2011;21(4):431–439. [PubMed: 20532833]

Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younoszai Z, Agrawal R, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology. 2011;53(6):1874–1882. [PubMed: 21360720]

Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011;54(5):1610–1619. [PMC free article: PMC3205292] [PubMed: 21748765]

Zelber-Sagi S, Buch A, Webb M, Yeshua H, Kiss O, Fliss N, et al. The effect of resistance training on non-alcoholic fatty liver disease (NAFLD) a randomized clinical trial. Journal of Hepatology. 2012;56:S526–S527.

Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M, et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology. 2006;4(5):639–644. [PubMed: 16630771]

Zelber-Sagi S, Buch A, Yeshua H, Vaisman N, Webb M, Harari G, et al. Effect of resistance training on non-alcoholic fatty-liver disease a randomized-clinical trial. World Journal of Gastroenterology. 2014;20(15):4382–4392. [PMC free article: PMC3989975] [PubMed: 24764677]

Zelber-Sagi S, Nitzan-Kaluski D, Halpern Z, Oren R. Prevalence of primary non-alcoholic fatty liver disease in a population-based study and its association with biochemical and anthropometric measures. Liver International. 2006;26(7):856–863. [PubMed: 16911469]